Back to results
US 2020/0347068 A1Published application
Small molecule myristate inhibitors of bcr-abl and methods of use
AssigneesDana-Farber Cancer Institute, Inc., The Scripps Research Institute
InventorsNathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers.
Claims19
A compound of formula IV, or a pharmaceutically acceptable salt thereof,
- wherein
- each R1 is independently selected from H, an optionally substituted C1-6alkyl, an optionally substituted C3-12cycloalkyl, an optionally substituted C3-12heterocycloalkyl, an optionally substituted C6-12aryl, an optionally substituted C3-12heteroaryl, an optionally substituted C1-6aralkyl, an optionally substituted C3-6heteroaralkyl, an optionally substituted C1-6haloalkyl, an optionally substituted (CH2)nC3-12heterocycloalkyl, an optionally substituted (CH2)nC6-12aryl, an optionally substituted (CH2)nC3-12heteroaryl, an optionally substituted (CH2)nC3-12cycloalkyl, (CH2)nC(O)Rx, (CH2)nC(O)OR, (CH2)nC(O)NRxRx, —C(O)Rx, —C(S)Rx, —C(NR)Rx, halo, C1-6haloalkyl, —S(O)Rx, —S(O)2Rx, or absent;
- Rx, for each occurrence, is independently, H, an optionally substituted C1-6alkyl, an optionally substituted C3-12cycloalkyl, an optionally substituted C3-12heterocycloalkyl, an optionally substituted C3-12aryl, an optionally substituted C3-12heteroaryl, or C1-6haloalkyl;
- and
- each n is independently 0, 1 or 2.
2 more elements
A compound, or a pharmaceutically acceptable salt thereof, selected from:
Dependencies are inferred from the claim text.